EGFR and diffuse large B-cell lymphoma: Our results presented herein warrant further examination of the therapeutic potential of already FDA-approved small molecule inhibitors as well as monoclonal antibodies targeting ERBB1 that could be repurposed for use in high-risk or relapsed DLBCL.